Sakhuja Rajeev, Kondabolu Krishnakanth, Córdova-Sintjago Tania, Travers Sean, Vincek Adam S, Kim Myong Sang, Abboud Khalil A, Fang Lijuan, Sun Zhuming, Canal Clinton E, Booth Raymond G
Department of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Department of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States; Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5000, United States.
Bioorg Med Chem. 2015 Apr 1;23(7):1588-600. doi: 10.1016/j.bmc.2015.01.060. Epub 2015 Feb 7.
Syntheses were undertaken of derivatives of (2S,4R)-(-)-trans-4-phenyl-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (4-phenyl-2-dimethylaminotetralin, PAT), a stereospecific agonist at the serotonin 5-HT2C G protein-coupled receptor (GPCR), with inverse agonist activity at 5-HT2A and 5-HT2B GPCRs. Molecular changes were made at the PAT C(4)-position, while preserving N,N-dimethyl substitution at the 2-position as well as trans-stereochemistry, structural features previously shown to be optimal for 5-HT2 binding. Affinities of analogs were determined at recombinant human 5-HT2 GPCRs in comparison to the phylogenetically closely-related histamine H1 GPCR, and in silico ligand docking studies were conducted at receptor molecular models to help interpret pharmacological results and guide future ligand design. In most cases, C(4)-substituted PAT analogs exhibited the same stereoselectivity ([-]-trans>[+]-trans) as the parent PAT across 5-HT2 and H1 GPCRs, albeit, with variable receptor selectivity. 4-(4'-substituted)-PAT analogs, however, demonstrated reversed stereoselectivity ([2S,4R]-[+]-trans>[2S,4R]-[-]-trans), with absolute configuration confirmed by single X-ray crystallographic data for the 4-(4'-Cl)-PAT analog. Pharmacological affinity results and computational results herein support further PAT drug development studies and provide a basis for predicting and interpreting translational results, including, for (+)-trans-4-(4'-Cl)-PAT and (-)-trans-4-(3'-Br)-PAT that were previously shown to be more potent and efficacious than their corresponding enantiomers in rodent models of psychoses, psychostimulant-induced behaviors, and compulsive feeding ('binge-eating').
开展了(2S,4R)-(-)-反式-4-苯基-N,N-二甲基-1,2,3,4-四氢萘-2-胺(4-苯基-2-二甲基氨基四氢萘,PAT)衍生物的合成工作。PAT是5-羟色胺5-HT2C G蛋白偶联受体(GPCR)的立体特异性激动剂,对5-HT2A和5-HT2B GPCR具有反向激动剂活性。在PAT的C(4)位进行分子修饰,同时保留2位的N,N-二甲基取代以及反式立体化学结构,先前已证明这些结构特征对5-HT2结合最为理想。与系统发育关系密切的组胺H1 GPCR相比,测定了类似物对重组人5-HT2 GPCR的亲和力,并在受体分子模型上进行了计算机辅助配体对接研究,以帮助解释药理结果并指导未来的配体设计。在大多数情况下,C(4)取代的PAT类似物在5-HT2和H1 GPCR上表现出与母体PAT相同的立体选择性([-]-反式>[+]-反式),尽管受体选择性各不相同。然而,4-(4'-取代)-PAT类似物表现出相反的立体选择性([2S,4R]-[+]-反式>[2S,4R]-[-]-反式),4-(4'-Cl)-PAT类似物的绝对构型通过单晶X射线晶体学数据得以证实。本文的药理亲和力结果和计算结果支持进一步开展PAT药物开发研究,并为预测和解释转化结果提供了依据,包括先前已证明在精神病、精神兴奋剂诱导行为和强迫性进食(“暴饮暴食”)的啮齿动物模型中比其相应对映体更有效和更具效力的(+)-反式-4-(4'-Cl)-PAT和(-)-反式-4-(3'-Br)-PAT。